Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.80
(
1.33%
)
Dow Jones
49,447.43
(
1.79%
)
Brent Oil
88.87
(
0.00%
)
Bitcoin
75,898.30
(
0.21%
)
News Focus
News Focus
Post# of 230
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

FACT-MASTER

Send PM Follow Ignore
Followers 30
Posts 4805
Boards Moderated 0
Alias Born 03/20/2011

FACT-MASTER

Re: Solarfuture post# 188

Monday, 09/16/2024 10:03:24 AM

Monday, September 16, 2024 10:03:24 AM

Post# of 230
I concur, the company appears to still be positive on IMA401 so there could be some other data they have. Also, these were all heavily pretreated patients, so patients that likely do not have any other alternative or their current therapies like chemo etc were not working.
imo, the Immatics therapy should be trialed as first line - chemo and other therapies actual cause certain mutations as far as i have researched, however the regulatory processes are just not that easy.

Stock is holding up well in early morning trading.

Looking forward to the data on IMA203 in October.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent IMTX News
More IMTX News